Trevi Therapeutics, Inc. (TRVI)
After hours:
| Previous Close | 2.7800 |
| Open | 2.7900 |
| Bid | 2.8900 x 100 |
| Ask | 2.9600 x 400 |
| Day's Range | 2.7800 - 2.9700 |
| 52 Week Range | 0.9700 - 4.0000 |
| Volume | |
| Avg. Volume | 301,669 |
| Market Cap | 202.743M |
| Beta (5Y Monthly) | 0.87 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Trevi Therapeutics (TRVI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Trevi Therapeutics (TRVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
- Zacks
Why Trevi Therapeutics (TRVI) Stock Might be a Great Pick
Trevi Therapeutics (TRVI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- Insider Monkey
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2023 Earnings Call Transcript
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2023 Earnings Call Transcript March 20, 2024 Trevi Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.08, expectations were $-0.1. TRVI isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to the […]
